Contribution of the CHEK2 1100delC variant to risk of multiple colorectal adenoma and carcinoma

被引:26
|
作者
Lipton, L
Fleischmann, C
Sieber, OA
Thomas, HJW
Hodgson, SV
Tomlinson, IPM
Houlston, RS
机构
[1] Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England
[2] London Res Inst, Mol & Populat Genet Lab, Canc Res UK, London WC2A 3PX, England
[3] St Marks Hosp, Canc Res UK Colorectal Unit, Harrow HA1 3UJ, Middx, England
[4] Guys Hosp, Dept Clin Genet, London SE1 9RT, England
关键词
CHEK2; 1100deIC; colorectal; neoplasm;
D O I
10.1016/S0304-3835(03)00391-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aneuploidy is a characteristic of a subset of colorectal tumours. CHEK2 (also known as CHK2) is one of the cell cycle checkpoint genes coding for a family of proteins that sense damage in eukaryotic cells. Germline variation in CHEK2 has recently been shown to confer cancer susceptibility. Heterozygous mutations have been identified in patients with TP53-negative Li-Fraumeni syndrome. Furthermore, the CHEK2 1100delC variant carried by 1% of the population has been shown to act as a low penetrance allele for both breast and prostate cancers. To further our knowledge about the contribution of CHEK2 1100delC to cancer incidence we have analysed a series of 149 patients with multiple colorectal adenomas some of whom developed colorectal cancer. The CHEK2 1100delC allele was not over-represented in cases suggesting that this variant is not associated with an increased risk of colorectal disease. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:149 / 152
页数:4
相关论文
共 50 条
  • [41] CHEK2 1100delC is present in familial breast cancer cases of the Basque Country
    Cristina Martínez-Bouzas
    Elena Beristain
    Isabel Guerra
    Javier Gorostiaga
    Jose-Luis Mendizabal
    Jose-Luis De-Pablo
    Eva García-Alegría
    Arantza Sanz-Parra
    Maria-Isabel Tejada
    Breast Cancer Research and Treatment, 2007, 103 : 111 - 113
  • [42] CHEK2*1100delC and Risk of Malignant Melanoma: Danish and German Studies and Meta-Analysis
    Weischer, Maren
    Heerfordt, Ida M.
    Bojesen, Stig E.
    Eigentler, Thomas
    Garbe, Claus
    Roecken, Martin
    Holmich, Lisbet Rosenkrantz
    Schmidt, Henrik
    Klyver, Helle
    Bastholt, Lars
    Nordestgaard, Borge G.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2012, 132 (02) : 299 - 303
  • [43] Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study
    L Mellemkjær
    C Dahl
    J H Olsen
    L Bertelsen
    P Guldberg
    J Christensen
    A-L Børresen-Dale
    M Stovall
    B Langholz
    L Bernstein
    C F Lynch
    K E Malone
    R W Haile
    M Andersson
    D C Thomas
    P Concannon
    M Capanu
    J D Boice
    J L Bernstein
    British Journal of Cancer, 2008, 98 : 728 - 733
  • [44] CHEK2 1100delC is present in familial breast cancer cases of the Basque Country
    Martinez-Bouzas, Cristina
    Beristain, Elena
    Guerra, Isabel
    Gorostiaga, Javier
    Mendizabal, Jose-Luis
    De-Pablo, Jose-Luis
    Garcia-Alegria, Eva
    Sanz-Parra, Arantza
    Tejada, Maria-Isabel
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 103 (01) : 111 - 113
  • [45] Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study
    Mellemkjaer, L.
    Dahl, C.
    Olsen, J. H.
    Bertelsen, L.
    Guldberg, P.
    Christensen, J.
    Borresen-Dale, A-L
    Stovall, M.
    Langholz, B.
    Bernstein, L.
    Lynch, C. F.
    Malone, K. E.
    Haile, R. W.
    Andersson, M.
    Thomas, D. C.
    Concannon, P.
    Capanu, M.
    Boice, J. D., Jr.
    Bernstein, J. L.
    BRITISH JOURNAL OF CANCER, 2008, 98 (04) : 728 - 733
  • [46] Age- and Tumor Subtype Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers
    Schmidt, Marjanka K.
    Hogervorst, Frans
    van Hien, Richard
    Cornelissen, Sten
    Broeks, Annegien
    Adank, Muriel A.
    Meijers, Hanne
    Waisfisz, Quinten
    Hollestelle, Antoinette
    Schutte, Mieke
    van den Ouweland, Ans
    Hooning, Maartje
    Andrulis, Irene L.
    Anton-Culver, Hoda
    Antonenkova, Natalia N.
    Antoniou, Antonis C.
    Arndt, Volker
    Bermisheva, Marina
    Bogdanova, Natalia V.
    Bolla, Manjeet K.
    Brauch, Hiltrud
    Brenner, Hermann
    Bruening, Thomas
    Burwinkel, Barbara
    Chang-Claude, Jenny
    Chenevix-Trench, Georgia
    Couch, Fergus J.
    Cox, Angela
    Cross, Simon S.
    Czene, Kamila
    Dunning, Alison M.
    Fasching, Peter A.
    Figueroa, Jonine
    Fletcher, Olivia
    Flyger, Henrik
    Galle, Eva
    Garcia-Closas, Montserrat
    Giles, Graham G.
    Haeberle, Lothar
    Hall, Per
    Hillemanns, Peter
    Hopper, John L.
    Jakubowska, Anna
    John, Esther M.
    Jones, Michael
    Khusnutdinova, Elza
    Knight, Julia A.
    Kosma, Veli-Matti
    Kristensen, Vessela
    Lee, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (23) : 2750 - +
  • [47] Homozygosity for a CHEK2* 1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype
    van Puijenbroek, M
    van Asperen, CJ
    van Mil, A
    Devilee, P
    van Wezel, T
    Morreau, H
    JOURNAL OF PATHOLOGY, 2005, 206 (02): : 198 - 204
  • [48] The CHEK2 1100delC allelic variant is not present in familial and sporadic breast cancer cases from Moroccan population
    Marouf, Chaymaa
    Hajji, Omar
    Diakite, Brehima
    Tazzite, Amal
    Jouhadi, Hassan
    Benider, Abdellatif
    Nadifi, Sellama
    SPRINGERPLUS, 2015, 4
  • [49] CHEK2* 1100delC screening of Asian women with a family history of breast cancer is unwarranted
    Lee, Ann S. G.
    Ang, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (14) : 2419 - 2419
  • [50] CHEK2*1100delC does not contribute to risk to breast cancer among Malay, Chinese and Indians in Malaysia
    Eswary Thirthagiri
    Leng San Cheong
    Cheng Har Yip
    Soo-Hwang Teo
    Familial Cancer, 2009, 8 : 355 - 358